Staff Briefs

The Clinical Trials Office has hired three new research assistants, Ryan Sorrentino, Christine Camacho, and Catherine Airda. They will be assisting research associates and team leaders in the office.

Marianne Davies, APRN, RN has been named the Director of Nursing for the section of Medical Oncology at Yale Cancer Center. Davies will be responsible for the management of the nursing staff within the section and will play a critical role in reviewing the current clinical practice procedures and developing standards of practice.

Theodore Holford, PhD, the Susan Dwight Bliss Professor of Epidemiology and Public Health, was elected a fellow of the American Statistical Association.

Yale Cancer Center has hired Margaret Kelley to help coordinate and manage special projects for the Center. Her first assignments include working on supportive care initiatives for cancer patients and the development of a patient resource center in the outpatient clinic.

Xiaomei Ma, PhD was awarded a two-year research grant by Hope Street Kids, a non-profit organization based in Virginia. Dr. Ma will be studying the role of immunological factors in the etiology of childhood acute lymphoblastic leukemia, the most common type of malignancy in children.

Kathleen Starick, RN has been named the Patient Services manager for the 9 West Medical Oncology Inpatient Unit and the Bone Marrow Transplant Unit on 8 West.

The Leslie H. Warner Postdoctoral Fellowships were awarded to Ralph Boettcher, PhD, Postdoctoral Associate, Molecular, Cellular & Developmental Biology, Tobin Cammell, PhD, Postdoctoral Fellow, Genetics, and Mindam Skakianos, Postdoctoral Associate, Molecular Biophysics and Biochemistry.

Sandra Watcke, RN, BS, MSN has been named Patient Services Manager in the Medical Oncology Treatment Center.

Women’s Health Research at Yale has funded Michael DiGiovanna, MD, PhD to study anti-estrogen drug combinations to inhibit lung cancer growth in men and women and determine whether the therapeutic effect is gender-specific.

Free Patient and Community Events

October 18, 2005 • 6:00 pm
YNH Shoreline Medical Center
Shoreline Medical Lecture Series
Early Detection and Treatment of Ovarian Cancer
Dr. Thomas Rutherford, Associate Professor of Obstetrics and Gynecology
Call 1.888.700.6543 for more information and reservations.

October 19, 2005 • 6:00 pm
YNH East Pavilion Cafeteria
Understanding Cancer Lecture Series
Stem Cell Transplant
Dr. Francine Foss, Professor of Medicine, Medical Oncology
Call 1.888.700.6543 for more information and reservations.

October 27, 2005 • 6:30 pm
James Blackstone Memorial Library, Branford
Taking Control of your Health and your Life: What Every Woman Needs to Know About Breast Cancer
Call 1.888.700.6543 for more information and reservations.

November 5, 2005 • 9:00 am
Harkness Auditorium, Yale School of Medicine
Y-Me Annual Breast Cancer Symposium
What’s New? 2005
Dr. Michael DiGiovanna, Associate Professor of Medicine, Medical Oncology
With a Panel of Presenters
Call 203.483.8200 for more information and reservations.

November 8, 2005 • 6:00 pm
YNH East Pavilion Cafeteria
Frankly Speaking About Lung Cancer: Stepping Back to Take a Closer Look
Dr. Frank Detterbeck, Professor and Section Chief of Thoracic Surgery
Dr. Lynn Tenover, Associate Professor of Internal Medicine
With a Panel of Presenters
Sponsored by the Wellness Community
Call 1.888.700.6543 for more information and reservations.

November 9, 2005 • 6:00 pm
YNH East Pavilion Cafeteria
Understanding Cancer Lecture Series
Coping with the Emotion of a Cancer Diagnosis
Dr. Jeanne Stein
Associate Professor of Psychiatry
Call 1.888.700.6543 for more information and reservations.

December 6, 2005 • 5:30-7:30 pm
Harkness Lounge, Yale School of Medicine
Patient and Family Holiday Party
Please join your physicians and nurses for an evening of celebration
Call 1.888.700.6543 for more information and reservations.

January 11, 2006 • 6:00 pm
YNH East Pavilion Cafeteria
Understanding Cancer Lecture Series
Chinese Herbal Medicine
Dr. Edward Chy, Chief of Medical Oncology
Call 1.888.700.6543 for more information and reservations.

CONTINUED FROM PAGE 1

“The convenience offered to cancer patients who are receiving regular radiation therapy treatments combined with the comfort of knowing that all the radiation therapists, physicists, nurses, and support staff are directly associated with Yale Cancer Center and Yale-New Haven Hospital has reduced the burden of cancer treatment for many patients along the Shoreline over the last year,” said Steve Bencivengo, Jr., Director of the Yale-New Haven Shoreline Medical Center.

The goal of radiation therapy is to kill cancer cells without harming the surrounding healthy tissue. More than half of all people with cancer undergo some form of radiation therapy as a part of their treatment plan. Offered at the Shoreline Radiation Oncology Center, external beam radiation therapy is the most widely used type of radiation therapy. The Shoreline Center offers Intensity Modulated Radiotherapy, Three Dimensional Radiotherapy, as well as conventional radiotherapy.

“This type of outreach program is a model of success for Yale Cancer Center. I expect to not only continue to deliver the best patient care in Guilford, but look forward to offering more clinical research and educational opportunities to our patients and families in the years to come,” Dr. Roberts said.

In addition to the Radiation Oncology Center, services at the Yale-New Haven Shoreline Medical Center for area residents include patient support groups, ambulatory surgery, diagnostic imaging, a hospital pre-admission office, laboratory medicine and blood work station, nuclear medicine testing, pathology services, and a nutrition center. In addition, an emergency services satellite, affiliated with Yale-New Haven Hospital’s Emergency Medicine Department, can triage and care for adults and children with emergency illnesses or injuries.

In collaboration with Dr. Roberts, Dr. Joseph Colasanto, Assistant Professor of Therapeutic Radiology, and Dr. Susan Higgins, Associate Professor of Therapeutic Radiology, also care for patients at the Shoreline Radiation Oncology Center. For more information on the Radiation Oncology Center, please call (203) 453-7170.
Advances in Allogeneic Transplantation at YCC

GIVE CANCER PATIENTS NEW OPTIONS

Cancer patients have more treatment options because of the groundbreaking clinical research being conducted at Yale Cancer Center within the Stem Cell Transplantation Program. Yale Cancer Center has expanded its program to include new techniques in transplantation, creating more opportunities for patients who would otherwise be ineligible for transplantation.

In an effort to destroy abnormal, cancerous cells in leukemia, lymphoma, and multiple myeloma, stem cell transplants are often used. The technique requires high doses of chemotherapy and radiation to kill the cancerous cells in the patient’s body followed by an infusion of donor stem cells to the bloodstream. The newly introduced stem cells then reproduce, replacing the eliminated cancer cells and rebuilding the immune system.

There are three obstacles to overcome to achieve a successful stem cell transplantation: the identification of a compatible donor; the patient's ability to withstand the high doses of chemotherapy and radiation prior to the transplant; and the avoidance of graft-versus-host disease, which occurs when the patient's body is attacked by the newly introduced stem cells. Researchers at Yale Cancer Center are actively investigating new and innovative solutions to these hurdles in an effort to make stem cell transplants a treatment option for a larger number of patients.

Currently, Yale Cancer Center is the only facility in Connecticut offering allogeneic transplantations, a transplant using donated stem cells. Moreover, the Center has expanded treatment options through clinical trials using haploidentical and non-myeloablative transplantations.

New opportunities are available for patients who have not been successfully matched with a donor and are at high risk for relapse. Available in only a handful of cancer centers in the country, the Yale Cancer Center is performing haploidentical transplants under the direction of Dr. Erkut Bahceci, Assistant Professor of Medicine, Medical Oncology.

Convenient Radiation Treatment

AT THE YALE-NEW HAVEN SHORELINE MEDICAL CENTER

Cancer patients who receive radiation therapy as a part of their treatment regimen have a convenient option at the Yale-New Haven Shoreline Medical Center. Recently celebrating its first anniversary in Guilford, CT, the facility allows cancer patients to receive their radiation therapy closer to home or work at this new facility. Led by Medical Director, Dr. Kenneth Roberts, Associate Professor of Therapeutic Radiology, the Center has seen over 200 patients in consultation and has served patients during over 4,800 treatment visits in the first year.

“The ability to offer external beam radiotherapy in Guilford has been extraordinarily convenient for those patients who live or work in the Shoreline area and the feedback we have received has been extremely positive.”

The ability to offer external beam radiotherapy in Guilford has been extraordinarily convenient for those patients who live or work in the Shoreline area and the feedback we have received has been extremely positive.

Like its flagship location in New Haven, the Shoreline Radiation Oncology Center uses a CT/simulator for precise treatment volume localization and delivers radiation treatments using a state-of-the-art linear accelerator. In addition to external beam radiation therapy treatments, full clinic services are also available including patient consultations and follow-up visits for patients who have completed their prescribed course of radiation therapy.

CONTINUED ON PAGE 6
The CUREchief Foundation Makes a Special Delivery to Patients

Loaded with their signature CUREchiefs for cancer patients, members of the CUREchief Foundation made a recent visit to the Yale-New Haven Hospital with UCONN Basketball player, Maria Conlon, the New Britain Rock Cats team mascot, and Ronald McDonald to cheer patients in the inpatient medical and pediatric oncology units.

The CUREchief foundation was founded in 2000 by Sandy Centorino and her two daughters in honor of her friend Patti, who had been diagnosed with cancer. The CUREchief is a simple triangle shape made to wear like a kerchief or as a scarf around the neck. The message is to bring hope and comfort to cancer patients receiving treatment.

“Never take for granted one small gesture or act of kindness that you could do for a friend in need. I never imagined that one simple triangle of fabric sent to my friend Patti could spread hope worldwide,” Ms. Centorino said. To date, CUREchiefs have been sent to hospitals and cancer centers throughout the world. The foundation makes an annual visit to Yale-New Haven Hospital and regularly sends CUREchiefs for our patients. For more information go to www.curechief.com

Below, Aurora Ismaili receives a surprise visit from Ronald McDonald during the annual CUREchief delivery. Bottom, the CUREchief delivery team greeted patients on the inpatient oncology floors of Yale-New Haven Hospital.

Dr. Kevin Kelly, a Nationally Recognized Expert in Prostate Cancer, Joins Yale Cancer Center

Recently appointed at Yale Cancer Center, W. Kevin Kelly, DO has been named an Associate Professor of Medicine in the Section of Medical Oncology. Dr. Kelly will lead the Prostate and Urologic Cancers disease unit in the Section of Medical Oncology of the Center, spearheading patient care and clinical research for prostate, bladder, kidney, and testicular cancer. In addition, he will play a key leadership role as Associate Director of Solid Tumor Clinical Investigation. In this position, Dr. Kelly will oversee the clinical development programs for solid tumors as well as direct the clinical trial operations for the Cancer Center.

“Dr. Kelly is nationally recognized for his pioneering work in developing innovative and more effective chemotherapy regimens for patients with advanced prostate cancer. We are delighted that, with his expertise and commitment to superior patient care, he will lead the Prostate and Urologic Cancers disease unit in the Section of Medical Oncology of the Center,” said Richard L. Edelson, Director of Yale Cancer Center.

Dr. Kelly has developed combined modality approaches for aggressive localized prostate cancer, using chemotherapy with radiation and/or surgery. He is currently focusing his clinical research on developing novel strategies to evaluate and treat prostate cancer. He is the principal investigator for several phase I, II, and III clinical trials for the treatment of advanced prostate cancer.

Prostate cancer is now the most common cancer diagnosed in American males and the second leading cause of cancer deaths in the United States. When caught early and treated appropriately, the majority of patients can be cured from their cancer. The organization of the Yale Prostate and Urologic Cancers Program at Yale Cancer Center offers patients easy access to specialized care for these cancers. As a multispecialty program, it is dedicated to providing cutting-edge technology for the evaluation, diagnosis, and treatment of prostate cancer and other urologic cancers.

“The appointment of Dr. Kelly to the medical oncology faculty at Yale Cancer Center is a phenomenal addition to our team. His expertise in urologic cancers has given significant strength to our program and will help us lead into a very exciting time in the treatment of prostate and urologic cancers,” said Dr. John Colberg, Associate Professor of Surgery, Urology.

Previously, Dr. Kelly served as an Associate Attending Physician, Genitourinary Oncology Service, Division of Solid Tumor Oncology, at Memorial Sloan-Kettering Cancer Center. Dr. Kelly currently serves a leadership role on several prominent national committees, including, the American Society of Clinical Oncology’s Localized Prostate Cancer Expert Panel and Chair of the Cancer and Leukemia Group B (CALGB) Prostate Cancer Committee for advanced prostate cancer.

The organization of the Yale Prostate and Urologic Cancers Program at Yale Cancer Center offers patients easy access to specialized care for these cancers. As a multispecialty program, it is dedicated to providing cutting-edge technology for the evaluation, diagnosis, and treatment of prostate cancer and other urologic cancers.

A graduate of Emory University, Dr. Kelly received his Doctor of Osteopathic Medicine from Philadelphia College of Osteopathic Medicine. He fulfilled his internship requirements at St. Joseph’s Hospital and his residency training in Internal Medicine at the Albert Einstein Medical Center, both in Philadelphia, PA. Dr. Kelly completed a fellowship in Medical Oncology at Memorial Sloan-Kettering Cancer Center.

Yale Cancer Center’s quarterly newsletter is written to inform the public and the Center’s friends, volunteers, donors, and staff on current items of interest at Yale Cancer Center. All inquiries should be addressed to the Yale Cancer Center Public Affairs Office, 135 College Street, Suite 200, New Haven, CT 06510-2483. Yale Cancer Center complies with the Health Insurance Portability and Accountability Act (HIPAA) of 1996.
M. Wasif Saif, MD, an Expert in Gastrointestinal Cancers

**APPOINTED AT YALE CANCER CENTER**

Dr. M. Wasif Saif, Associate Professor of Medicine, has joined the faculty in the section of Medical Oncology at Yale Cancer Center. Dr. Saif is an expert in gastrointestinal cancers, with a specific interest in pancreatic and colorectal cancers.

“Dr. Saif is one of the true rising stars in the field of gastrointestinal malignancies with a growing national and international reputation, and his appointment as a member of the GI cancer program in the Section of Medical Oncology at Yale Cancer Center is very well-deserved,” said Dr. Edward Chu, Chief of Medical Oncology.

Throughout his career, Dr. Saif has played a leading role in the development of novel anticancer agents and therapy regimens for the treatment of gastrointestinal malignancies.

Throughout his career, Dr. Saif has played a leading role in the development of novel anticancer agents and therapy regimens for the treatment of gastrointestinal malignancies. Dr. Saif's investigations into pancreatic cancer currently focus on the molecular biology of this disease and the identification of novel biological targets for drug development. He is also interested in improving upon the response and survival rates for colorectal cancer with the development of novel molecular and pharmacogenetic approaches for the treatment of this disease.

Gastrointestinal cancers, when combined, are the most common malignancy in the world. Dr. Saif's participation in the newly integrated Gastrointestinal Cancer Program at Yale Cancer Center brings specific expertise in pancreatic cancers to the interdisciplinary team of physicians.

Dr. Saif's participation in the newly integrated Gastrointestinal Cancer Program at Yale Cancer Center brings specific expertise in pancreatic cancers to the interdisciplinary team of physicians.

He is twice the recipient of the Outstanding Service Award from CancerCare for his contributions to cancer research and received the American Medical Association's Physician's Recognition Award for distinguished participation in CME. Dr. Saif serves on the editorial board of *Clinical Colorectal Cancer*, which is the only specialty journal in the United States that focuses on all aspects of colorectal cancer. In addition, he serves key leadership roles on various committees, including the National Comprehensive Cancer Network Committee for Colorectal Cancer, the Pancreatic Cancer Action Network, and the Eastern Cooperative Oncology Group Committee for Gastrointestinal Malignancies.

**Patient and Disease Information Expanded Online**

The Yale Cancer Center website has recently been redesigned to better meet the needs of our patients and their family members. While the content is continually changing and expanding, the primary goal of providing resources to our patients remains the focus of the site. The new website offers information on a number of different areas of interest to patients and the public, including:

- Information on the integrated, multidisciplinary cancer disease programs at Yale Cancer Center created to provide optimal care to our patients.
- Comprehensive disease information on the most common occurring cancers.
- Detailed descriptions of the clinical trials currently available for patients.
- Physician profiles of all medical oncologists, surgeons, radiation oncologists, pathologists, and diagnostic radiologists at Yale Cancer Center.
- A news section including news releases, publications, and links to Yale Cancer Center experts In the News.
- Calendars of patient events.

**U.S. News Best Hospitals**

U.S. News & World Report has recognized Yale-New Haven Hospital in its annual ranking of America’s Best Hospitals. Ranked in 11 of 17 specialties, Yale-New Haven ranked 24 for cancer services among the best cancer centers in the nation.
Haploidentical transplantations allow patients to be transplanted with mismatched or half-matched donor stem cells from a family member with whom they have only one haplotype in common. These transplants use an increased or “mega dose” of transplanted stem cells to enable the success of a mismatched transplant.

Dr. Stuart Seropian, Associate Professor of Medicine, Medical Oncology, is leading a clinical trial to offer non-myeloablative or reduced intensity transplants to patients at Yale Cancer Center. The technique uses a less intense treatment to prepare a patient for transplant and alternatively relies on the donor’s immune cells combined with newer agents to fight the cancer.

The ability to reduce the intensity of the transplant preparations has given patients who previously could not be considered for transplant a new opportunity. Standard allogeneic transplants are typically reserved for patients under the age of 55; of the 42 reduced intensity transplants done at Yale Cancer Center, 75% of the patients were over 55.

“This is a new option for patients whose age would preclude standard therapy. We have cared for several patients who have had successful transplants in their seventies,” Dr. Seropian said.

The third obstacle for transplant patients, graft-versus-host disease, is a common side effect of allogeneic transplants. “Graft-versus-host disease is the holy grail of stem cell transplants — How do you get the good results without the bad reaction?” asked Warren Shlomchik, MD, PhD, Associate Professor of Medicine, Medical Oncology and Associate Professor of Immunobiology.

Shlomchik has focused his research on developing methods to eliminate the development of graft-versus-host disease in allogeneic transplants, and he discovered that dendritic, or immune, cells were necessary in causing graft-versus-host disease.

Research has shown that the deletion of T cells from the donor stem cells removes the incidence of graft-versus-host, but may also decrease the effectiveness of the transplant. Recently receiving a Rapid Access to Intervention Development (RAID) grant from the Department of Health and Human Services to support his work, Dr. Shlomchik will investigate the induction of memory T cells in allogeneic transplants, which have been shown not to induce graft-versus-host disease.

In clinical studies that she pioneered, Dr. Francine Foss, Professor of Medicine, Medical Oncology, and Associate Director of the Hematologic Malignancies Program, has reduced the development of graft-versus-host disease in patients from the average of 40-50 percent to only 15 percent with the introduction of intravenous infusions of autologous immature dendritic cells before an allogeneic transplant. These findings have led to the initiation of two NCI-sponsored clinical trials to confirm these results in patients with lymphoma.

“The scientific advances in allogeneic transplants over the last several years have dramatically improved our ability to offer cancer patients new treatment options and options not offered at other facilities in Connecticut,” Dr. Dennis Cooper, Professor of Medicine, Medical Oncology, and Director of the Stem Cell Transplantation Program, explained.

“The number of allogeneic transplants performed at Yale Cancer Center has doubled in the last four years with the introduction of techniques such as non-myeloablative and haploidentical transplantations. Our goal is to continue to make new options available to patients at Yale Cancer Center,” Dr. Cooper said.

CONTINUED FROM PAGE 1

Yale Cancer Center Welcomes Four New Oncologists

Mayya Abu-Khalaf, MD

Yale Cancer Center is pleased to welcome Dr. Mayya Abu-Khalaf, a member of the multidisciplinary breast cancer disease team at Yale Cancer Center. Dr. Abu-Khalaf is working in close collaboration with members of the Departments of Surgery, Therapeutic Radiology, and Diagnostic Radiology to develop integrated clinical programs for patients with early-stage and locally advanced breast cancer. In addition, she is focusing on the development of novel treatment strategies for patients with metastatic breast cancer.

Dr. Abu-Khalaf received her Medical Degree from Jordan University School of Medicine, Amman, Jordan. She completed her internship and residency training in Internal Medicine and a fellowship in Medical Oncology at the Yale University School of Medicine, where her clinical research focus was in breast cancer.

Scott Gettinger, MD

Dr. Scott Gettinger, Assistant Professor of Medicine in the Section of Medical Oncology, has joined the clinical staff at Yale Cancer Center.

Dr. Gettinger received his Medical Degree from State University of New York at Brooklyn College of Medicine and completed his fellowship in Hematology and Medical Oncology at the Beth Israel Medical Center in New York. While there, he was actively involved with the Head and Neck Oncology Program.

“As a large referral center for head and neck cancers, Beth Israel was an ideal place to become familiar with the many challenges of caring for and treating patients with these devastating cancers. It is my intention to design and conduct clinical trials for head and neck cancer at Yale Cancer Center in hopes of improving the efficacy of current treatment modalities with particular attention to patients' quality of life,” Dr. Gettinger said.

Dr. Gettinger will be working closely with the Head and Neck Cancer Program to develop multidisciplinary approaches to treat patients with locally advanced disease and to develop innovative treatment regimens incorporating novel targeted agents. Newer strategies to prevent and treat complications of therapy will also be pursued.

Active in clinical research for lung cancer, Dr. Gettinger has also joined the Yale-New Haven Thoracic Oncology Program and will be involved in designing and launching clinical trials exploring newer treatment options for lung cancer patients. This multidisciplinary program promises to offer state-of-the-art care for those suffering from lung cancer.

James J. Lee, MD, PhD

Dr. James J. Lee, Assistant Professor of Medicine in the Section of Medical Oncology, is a key member of the Gastrointestinal Cancer Program at Yale Cancer Center and brings specific expertise in liver cancer to the program.

“The addition of Dr. Lee to the Gastrointestinal Cancer Program at Yale Cancer Center will give greater strength to the ongoing clinical research initiatives, creating increased treatment options for our patients through clinical trials,” Dr. Richard Edelson, Director of Yale Cancer Center, explained.

A graduate of the Seoul National University College of Medicine, Seoul, South Korea, Dr. Lee earned his PhD degree at The Johns Hopkins University School of Medicine. He completed his Internal Medicine residency training at the Long Island Jewish Medical Center before continuing on to the National Cancer Institute (NCI) to complete a fellowship in Medical Oncology. At the NCI, he focused his research on the development of new anti-cancer drugs for breast cancer, and has been involved in clinical development of an epothilone, a new generation of microtubule stabilizing agents.

Kenneth Miller, MD

Dr. Kenneth Miller, Assistant Professor of Medicine in the Section of Medical Oncology has been named the Director of Supportive Care Programs at the Center. Dr. Miller is an experienced physician who has focused his career on providing supportive care for cancer patients and will work to develop innovative clinical programs for both the inpatient and outpatient settings.

A graduate of Tufts University School of Medicine, Dr. Miller completed his internship and residency at Yale School of Medicine before going to the National Institutes of Health, where he completed a fellowship in Hematology. He continued his training at the Johns Hopkins Oncology Center as a Clinical Fellow in Medical Oncology. Dr. Miller is nationally known for his knowledge of patient survivorship issues and has been an invited speaker at cancer centers throughout the country addressing the topic Walking in our Patients’ Shoes – The Role of Empathy in Medicine. Prior to joining Yale, Dr. Miller served as the Associate Medical Director of the Connecticut Hospice. In 1993, he was awarded the Physician Recognition Award from the National Coalition for Cancer Survivorship.

In addition to his role of Director of Supportive Care Programs at Yale Cancer Center, he will serve as Medical Director of the proposed Connecticut Challenge Adult Survivorship Clinic scheduled to be launched late in 2006.
Over 200 riders showed their dedication to cancer survivors in the state by participating in the first annual Connecticut Challenge Bike ride, an event to raise money to fund Connecticut’s first adult survivorship clinic. The event, which raised over $250,000 in its inaugural year, was a culmination of many hours of hard work by volunteers led by Jeff Keith and John Ragland, Co-Directors of the Connecticut Challenge (CTC) and Bike Across America (BAA).

The leadership of Bike Across America has allocated the proceeds from the annual event to establish The Connecticut Challenge Adult Survivorship Clinic at Yale Cancer Center to address the needs of cancer survivors. The National Cancer Institute estimates that in 2000 there were nearly 10 million cancer survivors in the United States. The new clinic will provide screening for long-term consequences resulting from cancer treatment and information to help survivors minimize or avoid future health concerns.

“The enthusiasm of the riders, volunteers, and supporters at this year’s CTC ride was an inspiration. Their unyielding commitment to support cancer survivors in the state of Connecticut will result in specialized care for this increasing population. We are delighted that Bike Across America has chosen to contribute to the high-quality care provided at Yale Cancer Center through the creation of an adult survivorship clinic and continuing support of survivorship programs,” said Richard L. Edelson, Director, Yale Cancer Center.

Presenting sponsors included BMW of Bridgeport, Equipe Sport, Oakley, Orbea, and Patagonia. Suppliers for the event included Gatorade and Robert’s of Westport. For more information on the Connecticut Challenge, to contribute to the establishment of the Adult Survivorship Clinic at Yale Cancer Center, or to find out how to participate in next year’s ride on August 27, 2006, please go to www.ctchallenge.org.

Top to Bottom: 1. Members of the Yale Bulldogs Cycling team with former Olympians, Janel Jorgensen, Craig Beardsley, and Rowdy Gaines, along with Jeff Keith. 2. The Yale Pediatrics team, led by Dr. Jack van Hoff, kneeling. 3. Mitch McManus of BMW of Bridgeport awaits the start of the ride. 4. Dr. David Fimm and Maria Baquero, a student in his pathology lab. 5. Michelle Ross, John Ragland, and Louis Baldwin. 6. Dr. Richard Edelson and Dr. Lynn Wilson. 7. The riders start their 25, 50, and 100 mile rides. Photos by Elaine Uboh.